December 2020
Summary
The purpose of this technical report is to provide an analysis of the available information on methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]amino}butanoate (commonly known as MDMB-4en-PINACA), a synthetic cannabinoid receptor agonist that has recently emerged on the drug market in Europe, in order to support the risk assessment of the substance which has been requested by the European Commission in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended).
Explanatory note: In the interests of public health protection the EMCDDA is releasing this report before formal copy editing and page layout in the EMCDDA house style. The final report will be available in due course.
Table of contents
- Summary
- Chemical and physical properties, methods and the precursors used for manufacture or extraction
- Background
- Legitimate use
- Pharmacological and toxicological properties
- Extent and patterns of use, availability, and potential for diffusion
- Health risks Social risks
- Other relevant information
- References
Main subject:
Follow this news feed: EU